Compare · DHR vs IQV
DHR vs IQV
Side-by-side comparison of Danaher Corporation (DHR) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- DHR operates in Industrials, while IQV operates in Health Care - the two are in different parts of the market.
- DHR is the larger of the two at $124.65B, about 4.1x IQV ($30.15B).
- Over the past year, DHR is down 8.3% and IQV is up 24.2% - IQV leads by 32.6 points.
- DHR has been more active in the news (17 items in the past 4 weeks vs 7 for IQV).
- Both have 25 recent analyst ratings on file.
- Company
- Danaher Corporation
- IQVIA Holdings Inc.
- Price
- $176.12-2.12%
- $177.43-1.73%
- Market cap
- $124.65B
- $30.15B
- 1M return
- +0.56%
- +10.33%
- 1Y return
- -8.31%
- +24.25%
- Industry
- Industrial Machinery/Components
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NYSE
- IPO
- 2013
- News (4w)
- 17
- 7
- Recent ratings
- 25
- 25
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest DHR
- DZ Bank initiated coverage on Danaher with a new price target
- Wolfe Research resumed coverage on Danaher
- SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
- SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
- Citigroup resumed coverage on Danaher with a new price target
- Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board
- SVP, Human Resources Couchara Georgeann covered exercise/tax liability with 281 shares, decreasing direct ownership by 3% to 8,291 units (SEC Form 4)
- Director Filler Linda was granted 680 shares, increasing direct ownership by 3% to 24,712 units (SEC Form 4)
- Director Stevens Raymond C was granted 680 shares, increasing direct ownership by 5% to 13,728 units (SEC Form 4)
- Director Sanders A Shane was granted 680 shares, increasing direct ownership by 13% to 5,914 units (SEC Form 4)
Latest IQV
- IQVIA Announces Offering of Senior Notes
- IQVIA CEO to Speak at Jefferies Global Healthcare Conference
- IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A
- SEC Form 4 filed by Director Fasano Jim
- SEC Form 4 filed by Director Danhakl John G
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
- IQVIA CFO to Speak at Bank of America Health Care Conference 2026